MC1R and melanoma: Protection against oxidative lesions by MC1R agonists has been reported for WT MC1R, where it was most likely dependent on cAMP signaling [20]; however, a recent report showed its occurrence in melanoma cells of variant MC1R genotype, where it relied most likely on cAMP-independent signaling [25].